Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab

• Authors: Mohammad Khan, Emory University; Jack Arbiser, Emory University; Mary Lechowicz, Emory University; SA Westergaard, Emory University School of Medicine; M Harrington, Emory University School of Medicine; J Elsey, Emory University School of Medicine
• Journal Title: JAAD Case Reports
• Volume: Volume 6, Number 8
• Publisher: Elsevier | 2020-08-01, Pages 761-765
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1016/j.jdcr.2020.05.035
• Subjects: Biology, Cell; Biology, Radiation; Health Sciences, Oncology
• Keywords: CTCL, cutaneous T-cell lymphoma; PET/CT, positron emission tomography/computed tomography; TSEI, total skin electron irradiation; cutaneous T-cell lymphoma; gentian violet; mogalizumab; radiation

Abstract

Cutaneous T-cell lymphoma (CTCL) is a common cutaneous malignancy. Although early-stage disease is treatable with local therapies, including topical corticosteroids, retinoids, and alkylating agents, more advanced disease poses a therapeutic challenge. CTCL is highly radiation sensitive, but recurrence is common. Advanced disease is often lethal, with death caused by progression or bacterial sepsis from cutaneous infection.1 Many systemic treatments have been attempted for advanced disease, but complete remission is uncommon. More severe disease and poor outcomes are noted in African-Americans, making CTCL an example of racial disparities.